AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 21318581 — intervention group
Group type: COMPARATOR
Intervention: Stapled haemorrhoidopexy (SH)
Number of subjects: 52
Study 19500328 — intervention group
Group type: EXPERIMENTAL
Intervention: Microsatellite analysis (MA) of voided urine samples every 3 months with control cystoscopy at 3, 12, and 24 months
Number of subjects: 448
Study 19500328 — intervention group
Group type: COMPARATOR
Intervention: Cystoscopy of the urinary bladder every 3 months (conventional arm)
Number of subjects: 448
Study 19500328 — intervention group
Group type: EXPERIMENTAL
Intervention: Microsatellite analysis (MA) of voided urine samples
Number of subjects: 448
Study 16709935 — intervention group
Group type: EXPERIMENTAL
Intervention: Weight gain of 5% or less during the first 2 months of intensive phase therapy among underweight patients
Number of subjects: 857
Study 16709935 — intervention group
Group type: COMPARATOR
Intervention: Underweight at diagnosis
Number of subjects: 857
Study 16709935 — intervention group
Group type: COMPARATOR
Intervention: BMI less than 18.5 kg/m2
Number of subjects: 857
Study 15250174 — intervention group
Group type: EXPERIMENTAL
Intervention: Durodont medical fresh and white (RDA 70)
Number of subjects: 36
Study 15250174 — intervention group
Group type: EXPERIMENTAL
Intervention: Friscodent Zahnweiss (RDA 87)
Number of subjects: 36
Study 15250174 — intervention group
Group type: EXPERIMENTAL
Intervention: Combination of Durodont Zahnweiss intensiv (RDA 166) and Durodont medical fresh and white
Number of subjects: 36
Study 11486443 — intervention group
Group type: EXPERIMENTAL
Intervention: Nasal dilators
Number of subjects: 0
Study 11486443 — intervention group
Group type: COMPARATOR
Intervention: Placebo strip
Number of subjects: 0
Study 9272340 — intervention group
Group type: EXPERIMENTAL
Intervention: DTP-toxoids
Number of subjects: 3450
Study 9272340 — intervention group
Group type: COMPARATOR
Intervention: DT-toxoids
Number of subjects: 3450
Study 8339647 — intervention group
Group type: EXPERIMENTAL
Intervention: Selective decontamination of the digestive tract (SDD)
Number of subjects: 40
Study 8339647 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 40
Study 3712681 — intervention group
Group type: EXPERIMENTAL
Intervention: Nicotine gum
Number of subjects: 8
Study 3712681 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 8
Study 29883294 — intervention group
Group type: EXPERIMENTAL
Intervention: Autologous platelet-rich plasma (PRP)
Number of subjects: 8
Study 29883294 — intervention group
Group type: COMPARATOR
Intervention: Standard care (SoC)
Number of subjects: 8
Study 26874390 — intervention group
Group type: EXPERIMENTAL
Intervention: Beetroot Juice (BRJ) - 6.1 mmol nitrate, daily for 1 week
Number of subjects: 20
Study 26874390 — intervention group
Group type: COMPARATOR
Intervention: Beetroot Juice (BRJ) - 6.1 mmol nitrate, single acute dose
Number of subjects: 20
Study 24886619 — intervention group
Group type: EXPERIMENTAL
Intervention: Sling exercise training (ST)
Number of subjects: 38
Study 24886619 — intervention group
Group type: COMPARATOR
Intervention: Continuous passive motion (CPM)
Number of subjects: 38
Study 22269987 — intervention group
Group type: EXPERIMENTAL
Intervention: Workplace POWER program (n = 65)
Number of subjects: 110
Study 22269987 — intervention group
Group type: COMPARATOR
Intervention: Wait-list control group (n = 45)
Number of subjects: 110
Study 20304352 — intervention group
Group type: EXPERIMENTAL
Intervention: Warmed ropivacaine (body temperature) 0.75%
Number of subjects: 180
Study 20304352 — intervention group
Group type: EXPERIMENTAL
Intervention: Warmed ropivacaine (body temperature)
Number of subjects: 180
Study 20304352 — intervention group
Group type: COMPARATOR
Intervention: Room temperature ropivacaine
Number of subjects: 180
Study 17116056 — intervention group
Group type: EXPERIMENTAL
Intervention: Antenatal day care
Number of subjects: 395
Study 17116056 — intervention group
Group type: COMPARATOR
Intervention: Antenatal ward (control)
Number of subjects: 395
Study 14730655 — intervention group
Group type: EXPERIMENTAL
Intervention: Fluticasone propionate 50 mcg twice daily (FP 100)
Number of subjects: 30
Study 14730655 — intervention group
Group type: EXPERIMENTAL
Intervention: Fluticasone propionate 125 mcg twice daily (FP 250)
Number of subjects: 30
Study 14730655 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 30
Study 11344825 — intervention group
Group type: EXPERIMENTAL
Intervention: HRT (cyclical conjugated estrogens 0.625 mg/day plus medrogestone 5 mg/day)
Number of subjects: 54
Study 11344825 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 54
Study 11344825 — intervention group
Group type: EXPERIMENTAL
Intervention: HRT
Number of subjects: 54
Study 9150627 — intervention group
Group type: EXPERIMENTAL
Intervention: Intervention II
Number of subjects: 0
Study 8217793 — intervention group
Group type: EXPERIMENTAL
Intervention: Transfer Factor (TF)
Number of subjects: 22
Study 8217793 — intervention group
Group type: COMPARATOR
Intervention: Control (no TF)
Number of subjects: 22
Study 3622582 — intervention group
Group type: COMPARATOR
Intervention: delta-sleep-inducing peptide (DSIP)
Number of subjects: 14
Study 3622582 — intervention group
Group type: COMPARATOR
Intervention: placebo
Number of subjects: 14
Study 31834156 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravaginal ovule containing 0.03mg estriol, treated daily for 16 weeks (Group A)
Number of subjects: 96
Study 31834156 — intervention group
Group type: COMPARATOR
Intervention: Control group (Group B)
Number of subjects: 96
Study 30316952 — intervention group
Group type: EXPERIMENTAL
Intervention: Early ICU-team review
Number of subjects: 205
Study 28030601 — intervention group
Group type: EXPERIMENTAL
Intervention: Normal ionized calcium target range (1.1‐1.2 mmol/l)
Number of subjects: 30
Study 28030601 — intervention group
Group type: COMPARATOR
Intervention: Low ionized calcium target range (0.95‐1.05 mmol/l)
Number of subjects: 30
Study 24411798 — intervention group
Group type: EXPERIMENTAL
Intervention: Perceived positive school climates
Number of subjects: 361
Study 24411798 — intervention group
Group type: COMPARATOR
Intervention: Perceived student drug testing
Number of subjects: 361
Study 22446569 — intervention group
Group type: EXPERIMENTAL
Intervention: Mobile phone based monitoring (twice daily recording and mobile phone based transmission of symptoms, drug use, and peak flow with immediate feedback)
Number of subjects: 288
Study 22446569 — intervention group
Group type: EXPERIMENTAL
Intervention: Mobile phone based monitoring
Number of subjects: 288
Study 22446569 — intervention group
Group type: COMPARATOR
Intervention: Paper based monitoring
Number of subjects: 288
Study 20589762 — intervention group
Group type: EXPERIMENTAL
Intervention: health literacy (informational) intervention
Number of subjects: 87
Study 18931230 — intervention group
Group type: EXPERIMENTAL
Intervention: High fidelity group (n = 11)
Number of subjects: 22
Study 18931230 — intervention group
Group type: COMPARATOR
Intervention: Low fidelity group (n = 11)
Number of subjects: 22
Study 15910636 — intervention group
Group type: EXPERIMENTAL
Intervention: Non-milk drinkers
Number of subjects: 4024
Study 15910636 — intervention group
Group type: COMPARATOR
Intervention: Milk drinkers
Number of subjects: 4024
Study 15226691 — intervention group
Group type: EXPERIMENTAL
Intervention: Cotrimoxazole prophylaxis (one tablet per day)
Number of subjects: 530
Study 11176321 — intervention group
Group type: EXPERIMENTAL
Intervention: β‐glucan‐enriched bedtime snack
Number of subjects: 38
Study 11176321 — intervention group
Group type: COMPARATOR
Intervention: Conventional snack
Number of subjects: 38
Study 9431728 — intervention group
Group type: EXPERIMENTAL
Intervention: 1-session exposure and cognitive restructuring (3 hr session)
Number of subjects: 28
Study 9431728 — intervention group
Group type: COMPARATOR
Intervention: 5-sessions exposure and cognitive restructuring (6 hr gradual treatment)
Number of subjects: 28
Study 9431728 — intervention group
Group type: EXPERIMENTAL
Intervention: 1-session exposure and cognitive restructuring
Number of subjects: 28
Study 9431728 — intervention group
Group type: COMPARATOR
Intervention: 5-sessions exposure and cognitive restructuring
Number of subjects: 28
Study 7683222 — intervention group
Group type: EXPERIMENTAL
Intervention: Biofragmentable Anastomosis Ring (BAR)
Number of subjects: 150
Study 7683222 — intervention group
Group type: COMPARATOR
Intervention: Hand-suture
Number of subjects: 150
Study 7683222 — intervention group
Group type: COMPARATOR
Intervention: Sutures
Number of subjects: 150
Study 3306379 — intervention group
Group type: EXPERIMENTAL
Intervention: Haemophilus influenzae type b polysaccharide-diphtheria toxoid conjugate vaccine administered at 3, 4, 6, and 14 months.
Number of subjects: 60000
Study 3306379 — intervention group
Group type: COMPARATOR
Intervention: Control group (children born on even-numbered days).
Number of subjects: 60000
Study 28299947 — intervention group
Group type: EXPERIMENTAL
Intervention: Intervention: 'Start. Transform. Achieve. Results.'
Number of subjects: 693
Study 28299947 — intervention group
Group type: COMPARATOR
Intervention: Control
Number of subjects: 693
Study 28463161 — intervention group
Group type: EXPERIMENTAL
Intervention: PRO-CTCAE self-reporting during treatment
Number of subjects: 152
Study 28463161 — intervention group
Group type: EXPERIMENTAL
Intervention: PRO-CTCAE self-reporting after treatment
Number of subjects: 152
Study 25993047 — intervention group
Group type: EXPERIMENTAL
Intervention: Prophylactic extended-field carbon-ion radiotherapy (C-ion RT)
Number of subjects: 26
Study 24035250 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenous secukinumab (2×10 mg/kg)
Number of subjects: 30
Study 24035250 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 30
Study 21118028 — intervention group
Group type: EXPERIMENTAL
Intervention: Intensive school-based nutrition education and lifestyle interventions
Number of subjects: 106
Study 18492520 — intervention group
Group type: EXPERIMENTAL
Intervention: Lactobacillus reuteri ATCC 55730 (1 x 10(8) colony forming units a day) for 30 days
Number of subjects: 30
Study 18492520 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 30
Study 16565959 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.5 g/kg dose of alcohol
Number of subjects: 24
Study 16565959 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 24
Study 14571231 — intervention group
Group type: EXPERIMENTAL
Intervention: Growth hormone treatment (0.20 to 0.33 mg/kg body weight per week for 4 years)
Number of subjects: 38
Study 14571231 — intervention group
Group type: COMPARATOR
Intervention: Control group (untreated)
Number of subjects: 38
Study 10910439 — intervention group
Group type: EXPERIMENTAL
Intervention: Carvedilol
Number of subjects: 31
Study 10910439 — intervention group
Group type: EXPERIMENTAL
Intervention: Fosinopril
Number of subjects: 31
Study 10910439 — intervention group
Group type: COMPARATOR
Intervention: Healthy controls (no treatment)
Number of subjects: 31
Study 10910439 — intervention group
Group type: COMPARATOR
Intervention: Essential hypertension (no treatment)
Number of subjects: 31
Study 9010707 — intervention group
Group type: EXPERIMENTAL
Intervention: Matrix-type transdermal therapeutic system (MTTS)
Number of subjects: 34
Study 9010707 — intervention group
Group type: COMPARATOR
Intervention: Reservoir-type transdermal therapeutic system (RTTS)
Number of subjects: 34
Study 1558156 — intervention group
Group type: EXPERIMENTAL
Intervention: Captopril (25 mg/100 ml in 5 min)
Number of subjects: 42
Study 1558156 — intervention group
Group type: EXPERIMENTAL
Intervention: Clonidine (150 micrograms/100 ml)
Number of subjects: 42
Study 1558156 — intervention group
Group type: COMPARATOR
Intervention: Placebo (100 ml saline)
Number of subjects: 42
Study 1558156 — intervention group
Group type: EXPERIMENTAL
Intervention: Captopril and Clonidine
Number of subjects: 42
Study 4093327 — intervention group
Group type: EXPERIMENTAL
Intervention: Sweet sip feeds (chocolate, strawberry, banana)
Number of subjects: 36
Study 4093327 — intervention group
Group type: EXPERIMENTAL
Intervention: Savoury sip feeds
Number of subjects: 36
Study 4093327 — intervention group
Group type: EXPERIMENTAL
Intervention: Sweet sip feeds
Number of subjects: 36
Study 30639153 — intervention group
Group type: EXPERIMENTAL
Intervention: Standard speech pathology intervention (SPI) combined with supplemental pre‐recorded videos for home practice
Number of subjects: 18
Study 30639153 — intervention group
Group type: COMPARATOR
Intervention: Standard speech pathology intervention (SPI) alone
Number of subjects: 18
Study 31304554 — intervention group
Group type: EXPERIMENTAL
Intervention: Complete excision of the SCJ via endoscopic mucosal resection (EMR) in addition to radiofrequency ablation (RFA) ± EMR of BD/intramucosal EAC (experimental arm)
Number of subjects: 0
Study 31304554 — intervention group
Group type: COMPARATOR
Intervention: Current standard of care (RFA ± EMR) of said lesions (control arm)
Number of subjects: 0
Study 28414983 — intervention group
Group type: EXPERIMENTAL
Intervention: Hands-and-knees position
Number of subjects: 1400
Study 28414983 — intervention group
Group type: COMPARATOR
Intervention: Supine position
Number of subjects: 1400
Study 25569354 — intervention group
Group type: EXPERIMENTAL
Intervention: Active recovery protocol (2 min standing/walking, 16 min jogging at 58%±5% of VO2peak, 3 min standing/walking)
Number of subjects: 10
Study 25569354 — intervention group
Group type: COMPARATOR
Intervention: Passive recovery protocol (15 min sitting, 3 min walk/jog at 30% of VO2peak, 3 min standing/walking)
Number of subjects: 10
Study 23864249 — intervention group
Group type: EXPERIMENTAL
Intervention: Zoledronic acid (4 mg over a 30 min infusion) every 1 month
Number of subjects: 137
Study 23864249 — intervention group
Group type: COMPARATOR
Intervention: Clodronate (4 tablets per day of 1,600 mg)
Number of subjects: 137
Study 21081641 — intervention group
Group type: EXPERIMENTAL
Intervention: Enhanced Green Prescription intervention (written exercise prescription, brief advice from a primary care nurse, face-to-face follow-up at 6 months, and 9 months of telephone support)
Number of subjects: 1089
Study 21081641 — intervention group
Group type: EXPERIMENTAL
Intervention: Enhanced Green Prescription intervention
Number of subjects: 1089
Study 19293567 — intervention group
Group type: EXPERIMENTAL
Intervention: Alzheimer's Disease Assessment Scale ‐ Cognitive
Number of subjects: 489
Study 19293567 — intervention group
Group type: EXPERIMENTAL
Intervention: Clinical Dementia Rating
Number of subjects: 489
Study 19293567 — intervention group
Group type: EXPERIMENTAL
Intervention: Mini‐Mental State Examination
Number of subjects: 489
Study 19293567 — intervention group
Group type: EXPERIMENTAL
Intervention: Greater-than-average cognitive impairment
Number of subjects: 489
Study 19293567 — intervention group
Group type: EXPERIMENTAL
Intervention: Less-than-average cognitive impairment
Number of subjects: 489
Study 16729276 — intervention group
Group type: EXPERIMENTAL
Intervention: Transdermal fentanyl (TDF)
Number of subjects: 399
Study 16729276 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 399
Study 15503310 — intervention group
Group type: EXPERIMENTAL
Intervention: Irinotecan once every 3 weeks
Number of subjects: 291
Study 15503310 — intervention group
Group type: COMPARATOR
Intervention: Weekly irinotecan treatment
Number of subjects: 291
Study 11317685 — intervention group
Group type: EXPERIMENTAL
Intervention: Titanium implants
Number of subjects: 31
Study 11317685 — intervention group
Group type: COMPARATOR
Intervention: Stainless steel implants
Number of subjects: 31
Study 9446435 — intervention group
Group type: EXPERIMENTAL
Intervention: Indomethacin (100 mg on the day of operation and 3 x 25 mg orally from postoperative day 1 to 10)
Number of subjects: 50
Study 9446435 — intervention group
Group type: COMPARATOR
Intervention: Single dose of 6 Gy radiation (administered within postoperative days 1 to 4)
Number of subjects: 50
Study 7957539 — intervention group
Group type: EXPERIMENTAL
Intervention: Glycopyrrolate (1 mg i.v.)
Number of subjects: 12
Study 7957539 — intervention group
Group type: COMPARATOR
Intervention: Captopril (75 mg orally)
Number of subjects: 12
Study 7957539 — intervention group
Group type: COMPARATOR
Intervention: Placebo (matched to captopril, orally)
Number of subjects: 12
Study 3311818 — intervention group
Group type: EXPERIMENTAL
Intervention: QU.A.RT. group (irradiated on the operated breast with a total dose of 50 Gy plus a limited boost of 10 Gy)
Number of subjects: 701
Study 3311818 — intervention group
Group type: COMPARATOR
Intervention: Halsted group (not irradiated)
Number of subjects: 701
Study 30703663 — intervention group
Group type: EXPERIMENTAL
Intervention: Self-initiated gradual reduction (at least 25% reduction in cigarettes per day)
Number of subjects: 482
Study 30703663 — intervention group
Group type: COMPARATOR
Intervention: No reduction or increase in smoking
Number of subjects: 482
Study 28069156 — intervention group
Group type: EXPERIMENTAL
Intervention: Progressive Muscle Relaxation (PMR) and Guided Imagery (GI)
Number of subjects: 54
Study 28069156 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 54
Study 25791747 — intervention group
Group type: EXPERIMENTAL
Intervention: Healthy school meal programme
Number of subjects: 693
Study 25791747 — intervention group
Group type: COMPARATOR
Intervention: Control (usual packed lunch from home)
Number of subjects: 693
Study 23364497 — intervention group
Group type: EXPERIMENTAL
Intervention: Probiotics-containing biscuit
Number of subjects: 32
Study 23364497 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 32
Study 21522034 — intervention group
Group type: EXPERIMENTAL
Intervention: Coping skills training
Number of subjects: 181
Study 21522034 — intervention group
Group type: COMPARATOR
Intervention: Group educational intervention
Number of subjects: 181
Study 19207131 — intervention group
Group type: EXPERIMENTAL
Intervention: blue-appearing light (goLITE)
Number of subjects: 18
Study 19207131 — intervention group
Group type: EXPERIMENTAL
Intervention: blue-enriched white-appearing light
Number of subjects: 18
Study 16418883 — intervention group
Group type: EXPERIMENTAL
Intervention: [11C]metahydroxyephedrine (mHED) PET
Number of subjects: 14
Study 16418883 — intervention group
Group type: EXPERIMENTAL
Intervention: [18F]fluorodeoxyglucose (FDG) PET
Number of subjects: 14
Study 16418883 — intervention group
Group type: COMPARATOR
Intervention: MIBG
Number of subjects: 14
Study 16418883 — intervention group
Group type: EXPERIMENTAL
Intervention: PET scanning (mHED and FDG)
Number of subjects: 14
Study 16418883 — intervention group
Group type: EXPERIMENTAL
Intervention: PET functional imaging
Number of subjects: 14
Study 15589635 — intervention group
Group type: EXPERIMENTAL
Intervention: Percutaneous revascularization (PTCA, n=109)
Number of subjects: 212
Study 15589635 — intervention group
Group type: COMPARATOR
Intervention: Medical therapy (n=103)
Number of subjects: 212
Study 12623472 — intervention group
Group type: EXPERIMENTAL
Intervention: Two-layered repair
Number of subjects: 823
Study 12623472 — intervention group
Group type: COMPARATOR
Intervention: Three-layered repair
Number of subjects: 823
Study 9707354 — intervention group
Group type: EXPERIMENTAL
Intervention: 20 mg manidipine dihydrochloride
Number of subjects: 20
Study 9707354 — intervention group
Group type: COMPARATOR
Intervention: Healthy subjects (control group)
Number of subjects: 20
Study 9707354 — intervention group
Group type: EXPERIMENTAL
Intervention: Patients with grade B hepatic impairment
Number of subjects: 20
Study 7880702 — intervention group
Group type: EXPERIMENTAL
Intervention: suxamethonium 0.25 mg kg‐1
Number of subjects: 60
Study 7880702 — intervention group
Group type: EXPERIMENTAL
Intervention: suxamethonium 0.5 mg kg‐1
Number of subjects: 60
Study 7880702 — intervention group
Group type: COMPARATOR
Intervention: No suxamethonium (Control)
Number of subjects: 60
Study 7880702 — intervention group
Group type: COMPARATOR
Intervention: Propofol and alfentanil alone (Control)
Number of subjects: 60
Study 2099158 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenous ampicillin (2 gm) and sulbactam (1 gm)
Number of subjects: 6
Study 2099158 — intervention group
Group type: EXPERIMENTAL
Intervention: Intraperitoneal ampicillin (2 gm) and sulbactam (1 gm)
Number of subjects: 6
Study 2099158 — intervention group
Group type: EXPERIMENTAL
Intervention: Intraperitoneal ampicillin/sulbactam (2 gm/1 gm)
Number of subjects: 6
Study 33875 — intervention group
Group type: EXPERIMENTAL
Intervention: Sulphasalazine (2 g/day)
Number of subjects: 70
Study 33875 — intervention group
Group type: COMPARATOR
Intervention: High dose sodium cromoglycate (2 g/day)
Number of subjects: 70
Study 33875 — intervention group
Group type: COMPARATOR
Intervention: Low dose sodium cromoglycate (160 mg/day)
Number of subjects: 70
Study 30248269 — intervention group
Group type: EXPERIMENTAL
Intervention: MJ-SJ (multi-joint exercises followed by single-joint exercises)
Number of subjects: 36
Study 30248269 — intervention group
Group type: COMPARATOR
Intervention: SJ-MJ (single-joint exercises followed by multi-joint exercises)
Number of subjects: 36
Study 30248269 — intervention group
Group type: EXPERIMENTAL
Intervention: MJ-SJ
Number of subjects: 36
Study 30248269 — intervention group
Group type: COMPARATOR
Intervention: SJ-MJ
Number of subjects: 36
Study 29039261 — intervention group
Group type: EXPERIMENTAL
Intervention: High-intensity exercise program (9-month, thrice-weekly, 10-minute sessions)
Number of subjects: 240
Study 29039261 — intervention group
Group type: COMPARATOR
Intervention: Control group (no exercise intervention)
Number of subjects: 240
Study 27343147 — intervention group
Group type: EXPERIMENTAL
Intervention: Home BP telemonitoring alone
Number of subjects: 300
Study 27343147 — intervention group
Group type: EXPERIMENTAL
Intervention: Home BP telemonitoring plus protocolized pharmacist case management
Number of subjects: 300
Study 27343147 — intervention group
Group type: COMPARATOR
Intervention: Enhanced usual care
Number of subjects: 300
Study 27343147 — intervention group
Group type: EXPERIMENTAL
Intervention: Home BP telemonitoring alone and Home BP telemonitoring plus protocolized pharmacist case management
Number of subjects: 300
Study 24698817 — intervention group
Group type: EXPERIMENTAL
Intervention: Mobile-bearing TKA
Number of subjects: 40
Study 24698817 — intervention group
Group type: COMPARATOR
Intervention: Fixed-bearing TKA
Number of subjects: 40
Study 22722502 — intervention group
Group type: EXPERIMENTAL
Intervention: Cognitive-behavioral weight management intervention
Number of subjects: 222
Study 19047322 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 19047322 — intervention group
Group type: EXPERIMENTAL
Intervention: Fluoxetine (after excluding one large trial)
Number of subjects: 0
Study 19047322 — intervention group
Group type: COMPARATOR
Intervention: Recent studies (multisite trials)
Number of subjects: 0
Study 17612822 — intervention group
Group type: EXPERIMENTAL
Intervention: Citalopram (40 mg/day) plus placebo
Number of subjects: 60